FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Legault Pierre (Last) (First) (Middle)						Syndax Pharmaceuticals Inc [SNDX] 3. Date of Earliest Transaction (Month/Day/Year) 08/05/2022									all applic	able)	g Pers	10% Ov Other (s below)	vner
C/O SYNDAX PHARMACEUTICALS, INC. 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3						If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WALTH	AM M	^A A	02451		_									X	Form filed by One Re Form filed by More th Person			•	
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
D		2. Transaction Date (Month/Day/Yea		Execution Date,		Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			Benefic Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	ount (A) or Price			Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock				08/05/2	/05/2022				M		10,000	A	\$9.6	3	42,	42,000		D	
Common Stock 08/05/					2022)22					10,000	D	\$23.015	0159(2) 3		2,000		D	
Common Stock 08/05/20					2022	22			M		14,000	A	\$8.9	\$8.93		46,000		D	
Common Stock 08/05/20					2022	22			S ⁽¹⁾		14,000	D	\$23.015	23.0159(2)		32,000		D	
		-	Table I								posed of,				wned		,		Λ_
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any		4. Transa Code (8)	action	5. Number of		6. Date Exer Expiration I (Month/Day/		cisable and	7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		nt 8.	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e C S F Illy C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares	r					
Stock Options (Right to buy)	\$9.63	08/05/2022			M			10,000	(3)	02/08/2028	Common Stock	10,00	0	\$0.00	0.00		D	
Stock Options (Right to buy)	\$8.93	08/05/2022			M			14,000	(3)	05/23/2028	Common Stock	14,00	0	\$0.00	0.00		D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 39,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.
- 2. The sale prices ranged from \$23.00 to \$23.12
- 3. This option is fully vested

Remarks:

/s/ Michael A. Metzger, as Attorney-in-Fact

08/09/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).